{"entity":{"id":"aveta-biomics","kind":"company","name":"Aveta Biomics","aka":["Aveta Biomics, Inc."],"tldr":"Aveta Biomics is a United States-based biotechnology company running 2 late-stage cancer trials of APG-157 in glioma & glioblastoma and head and neck squamous cell carcinoma.","summary":"Aveta Biomics, based in Bedford, the United States, is a biotechnology company. Aveta Biomics develops oral immunotherapies for cancer that apply principles of evolutionary biology to reprogram the tumour-immune ecosystem upstream of checkpoint pathways. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing APG-157 in glioma & glioblastoma and head and neck squamous cell carcinoma. The largest, NCT06011109 (Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab), plans to enrol 30 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://avetabiomics.com"},{"label":"ClinicalTrials.gov: trials led by Aveta Biomics","url":"https://clinicaltrials.gov/search?lead=Aveta%20Biomics%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["glioblastoma","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06011109","nct05312710"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Bedford","country":"US","companyType":"biotech","website":"https://avetabiomics.com","stage":"startup","investors":[],"funding":[]},"route":"/companies/aveta-biomics/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"trial":[{"id":"nct05312710","kind":"trial","name":"Safety and Efficacy of APG-157 in Head and Neck Cancer","route":"/trials/nct05312710/"},{"id":"nct06011109","kind":"trial","name":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab","route":"/trials/nct06011109/"}]}}